Arsanis Public Company

Primary contact
Waltham, Massachusetts, United States

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis' monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. This approach, according to Arsanis, provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.
Primary contact
Waltham, Massachusetts, United States

Funding 💰

Total $100.3M
Select investors OrbiMed, Polaris Partners, SV Health Investors, NeoMed Management, EMBL Ventures, Bill & Melinda Gates Foundation, GV
Last update: May 9, 2018